+251% in realized profits for me yesterday. If volume picks up in markets today, I’ll be challenging myself to match that number trading securities on which Stifel, Nicolaus & Company, Incorporated is currently doing due diligence.
| Ticker Code | Ticker Name | Ticker Industry | Price Change | Average Volume (50)* |
| TTNP | Titan Pharmaceuticals, Inc. common stock | Biotechnology | 14.81% | 10,710,521 |
| IBIO | Ibio Inc | Biotechnology | 23.19% | 14,024,336 |
| FREQ | Frequency Therapeutics Inc | Biotechnology | 8.20% | 130,220 |
| OMER | Omeros Corporation | Biotechnology | 9.54% | 525,628 |
| SLS | Sellas Life Sciences Group Inc | Biotechnology | 46.44% | 195,907 |
| TBLT | Toughbuilt Industries Inc | Tools & Accessories | -14.96% | 3,635,946 |
| HSITF | Hadasit Bio Holding Ltd. | Biological products, except diagnostic | 0.00% | OTC – 3 |
| TGTX | TG Therapeutics Inc common stock | Biotechnology | 52.76% | 2,708,097 |
| PYPL | Paypal Holdings Inc | Credit Services | 36.57% | 10,416,053 |
| CSCO | Cisco Systems, Inc. | Communication Equipment | 13.49% | 23,792,304 |
| NFLX | Netflix Inc | Entertainment | 16.12% | 9,551,464 |
| HTBX | Heat Biologics Inc | Biotechnology | 24.00% | 6,522,272 |
| TTOO | T2 Biosystems Inc | Diagnostics & Research | 4.41% | 9,532,221 |
| SRNE | Sorrento Therapeutics Inc | Biotechnology | 67.72% | 35,548,290 |
| SQ | Square Inc | Software – Infrastructure | 36.15% | 15,618,337 |
| BW | Babcock & Wilcox Enterprises Inc | Specialty Industrial Machinery | 49.00% | 489,760 |
| BABA | Alibaba Group Holding Ltd – ADR | Internet Retail | 10.29% | 18,188,810 |
| HD | Home Depot Inc | Home Improvement Retail | 21.61% | 5,728,792 |
| ADMP | Adamis Pharmaceuticals Corp | Drug Manufacturers – Specialty & Generic | 23.40% | 1,958,790 |
| MT | ArcelorMittal SA | Banks – Diversified | 0.43% | 6,624,858 |
Every sector in the stock market has leaders and laggards. Oftentimes, many companies quietly rise from being a fair-to-middling stock to one that is perceived as“the next big thing” in its respective sector.
I think I’ve found one of those today, suspecting the company’s recent news and financial professional sentiment are indicative of the company’s future, at least in the short-term.
TG Therapeutics (NYSE: TGTX) isn’t a heavily traded name such as Gilead or Pfizer, but in recent weeks TGTX has doubled in price-per-share, received two upgrades, and announced positive preclinical data on a cancer drug it’s testing.
Now why are financial institutions taking a look at the company and maybe even making moves on it? We don’t know for sure, but maybe TGTX could be next in line to test a COVID-19 vaccine, or maybe the company announces more positive data on its new cancer drug.
Either way, Wall Street views positive data reported by biotech companies as bullish much more often than not, and sometimes even if a company’s long-term prosperity is questionable, its price can still surge in the short-term. We just saw an example of that yesterday with INO!
Now for the fun part… How I want to trade TGTX alongside Wall Street’s brightest minds today or in the days ahead.
TGTX is forming a classic stair-stepper pattern, which is a bullish trend. Currently trading right above $20/share support, should the stock rise and markets make a red-to-green move, this stock does indeed have room to run toward $25/share.
The path of least resistance for this stock is to the upside – there isn’t much of a bearish trading opportunity on TGTX today. The stock is also in a clear uptrend as indicated by the chart above – unless that changes, I don’t want to bet against this trend!
I’ll be looking for options sweeps and dark pool activity on this name today and in the days ahead… I suspect Wall Street’s heaviest hitters will be buying into this one, if they haven’t already!
Yours for TrackStar trading,
Davis Martin
America’s #1 Premarket and Day Trader
Disclaimer: This is not investment advice. This article is for information purposes only and opinion-based on financial advisor data across a selection of websites. Investors should be cautious about any and all investments and are advised to conduct their own due diligence prior to making any investment decisions.